Analytical Testing

The control of pharmaceutical impurities is a fundamental objective in the development of drugs, focusing on the comprehension of the chemical structures of unidentified impurities. This understanding is essential for evaluating toxicological ... read more

In the ever-evolving landscape of pharmaceutical development, ensuring the safety and efficacy of drug products is paramount. One critical aspect of this process is the accurate determination of elemental impurities, which can have significant ... read more

Personalized medicine (i.e., “precision medicine”) is revolutionizing healthcare by tailoring treatments to individual patients. It’s an approach that moves away from the traditional one-size-fits-all treatment model and instead customizes medical ... read more

Sentinel Capital Partners, a private equity firm that invests in promising lower middle market companies, today announced its acquisition of WellSpring Pharmaceutical Corporation, a North American manufacturer and marketer of specialty prescription and over-the-counter pharmaceuticals. Sentinel completed the transaction alongside Ancor Capital Partners, an independent sponsor with extensive healthcare expertise. read more

To provide a more comprehensive and efficient global solution for its laboratory customers, Quintiles today announced the signing of a definitive agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory providing Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing and other services. Under the agreement, Quintiles will acquire Advion BioServices for an undisclosed amount of cash. Completion of the transaction, which is subject to usual and customary conditions, is expected this quarter. At that time it will join Quintiles as Advion Bioanalytical Labs, a Quintiles company. read more

Catalent Pharma Solutions, a leading global drug delivery technology company, and NewMarket Pharmaceuticals LLC have entered into an agreement to jointly formulate and develop a portfolio of products for treating production and companion animals using Catalent’s proprietary, market-leading Zydis® fast-dissolve technology and NewMarket’s DSI™ platform (Direct Systemic Introduction, patent pending). read more

The manufacture of protein-based drugs is complex and relies on using biological host systems. This can result in small changes in protein structure during production and formation of protein variants... read more